Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs
As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi.
In exchange for the global rights to the assets, Sanofi will get up to USD 353 million, including a USD 2.25 million upfront fee and potential development, regulatory and commercial milestone payments down the line as per securities filing.
The programs, licensed from Sanofi’s Bioverativ unit, work differently than Oxbryta, which halts the polymerisation, sickling, haemoglobin S, and a...
